Kerecis Real-World Fish Skin Graft Registry
Launched by KERECIS LTD. · Apr 22, 2024
Trial Information
Current as of July 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This observational (i.e., non-interventional), post-market, real-world, Registry was designed to collect, analyze, and identify relevant safety and performance outcomes for "all comers" using Kerecis devices in routine medical practice within a wide variety of United States (US) medical practice settings. These clinical data will be used at Kerecis for many purposes, which include, but are not limited to, device safety and performance evaluation as part of routine patient care and post-market clinical follow-up data commitments to regulatory authorities around the world.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provided informed consent
- • Has at least one target wound treated with a Kerecis device according to physician medical judgement within one calendar month prior to the registry enrollment date
- Exclusion Criteria:
- • None
About Kerecis Ltd.
Kerecis Ltd. is a pioneering biotechnology company focused on developing regenerative medicine solutions through the use of fish skin as a biologic alternative for wound healing and tissue regeneration. Leveraging advanced scientific research and innovative technology, Kerecis aims to address unmet medical needs in the treatment of chronic wounds, surgical wounds, and soft tissue reconstruction. The company's commitment to enhancing patient outcomes is reflected in its robust clinical trial programs, which are designed to validate the safety and efficacy of its products. By harnessing the natural properties of fish skin, Kerecis Ltd. is at the forefront of transforming wound care and improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sarasota, Florida, United States
Sarasota, Florida, United States
Greensboro, North Carolina, United States
Beavercreek, Ohio, United States
Columbus, Ohio, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Anne Swearingen
Principal Investigator
Kerecis Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported